Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer - Episode 14

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

, , , , ,

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Current mCRC Treatment Landscape
    EP. 2: Evaluating 3L Treatment Landscape Evolution
    EP. 3: Fruquintinib MoA and Toxicity Profile Overview
    EP. 4: Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
    EP. 5: FRESCO-2 Study Highlights
    EP. 6: Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
    EP. 7: Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
    EP. 8: Consideration for Fruquintinib Dosing and Titration
    EP. 9: Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
    EP. 10: Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
    EP. 11: Considerations for Platinum-based Therapy
    EP. 12: Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
    EP. 13: Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
    Now Viewing
    EP. 14: Data Surrounding Treatment for MSI-high Patients from ASCO 2024
    EP. 15: Unmet Needs Surrounding mCRC Treatment
    EP. 16: Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
    x